SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Weekly Recap: IMVT-1402 halted for cutaneous lupus and FcRn programs

Roivant Sciences Ltd. (NASDAQ:ROIV) halted IMVT-1402’s cutaneous lupus program after a 12-week trial missed its primary endpoint, sending shares lower, while refocusing the asset on other autoimmune uses and prioritizing commercialization of FcRn programs for Graves' disease and uveitis.Previous We…

ROIV

Related stories